The Valley Desk

NCT01885208 · Interventional trial

Efficacy and Safety of Semaglutide Once-weekly Versus Exenatide ER 2.0 mg Once-weekly as add-on to 1-2 Oral Antidiabetic Drugs (OADs) in Subjects With Type 2 Diabetes

Overall registry status Completed

Phase 3

Conditions Diabetes, Diabetes Mellitus, Type 2

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov